Philippines - English - FDA (Food And Drug Administration)

caan pharmaceutical co., inc.; distributor: largen med inc. - furosemide - solution for injection (im/iv) - 10 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ranitidine hydrochloride, quantity: 168 mg (equivalent: ranitidine, qty 150 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; hypromellose; castor oil; iron oxide yellow; titanium dioxide; purified talc - indicated for short-term treatment of proven duodenal ulcer and gastric ulcer; maintenance treatment to reduce the risk of relapse in duodenal ulcer; maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer; treatment of gastrinoma (zollinger-ellison syndrome); short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids; maintenance treatment to reduce the risk of relapse of reflux oesophagitis; treatment of scleroderma oesophagitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ranitidine hydrochloride, quantity: 336 mg (equivalent: ranitidine, qty 300 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; hypromellose; castor oil; iron oxide yellow; titanium dioxide; purified talc - indicated for short-term treatment of proven duodenal ulcer and gastric ulcer; maintenance treatment to reduce the risk of relapse in duodenal ulcer; maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer; treatment of gastrinoma (zollinger-ellison syndrome); short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids; maintenance treatment to reduce the risk of relapse of reflux oesophagitis; treatment of scleroderma oesophagitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ranitidine hydrochloride, quantity: 335.8 mg (equivalent: ranitidine, qty 300 mg) - tablet, film coated - excipient ingredients: polydextrose; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; vanillin; carnauba wax; titanium dioxide; hypromellose - duodenal ulcer: short-term treatment of proven duodenal ulcer, maintenance treatment to reduce the risk of relapse in duodenal ulcer. gastric ulcer: short-term treatment of proven gastric ulcer, maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. reflux oesophagitis: short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative antireflux measures and simple drug therapies such as antacids. maintenance treatment to reduce risk of relapse of reflux oesophagitis. scleroderma oesophagitis: treatment of scleroderma oesophagitis. zollinger-ellison syndrome: treatment of gastrinoma (zollinger-ellison syndrome).

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 168 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; triacetin - 1. short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. treatment of gastrinoma (zollinger-ellison syndrome). 5. short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. treatment of scleroderma oesophagitis. the intravenous injection is indicated where oral treatment is inappropriate

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 336 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; triacetin - . short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. treatment of gastrinoma (zollinger-ellison syndrome). 5. short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. treatment of scleroderma oesphagitis. the intravenous injection is indicated where oral treatment is inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 168 mg (equivalent: ranitidine, qty 150 mg) - tablet, effervescent - excipient ingredients: sodium benzoate; povidone; sodium bicarbonate; monosodium dihydrogen citrate; aspartame; flavour - short term treatment of proven duodenal and gastric ulcer. maintenance treatment to reduce the risk of relapse in duodenal ulcer. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. treatment of gastrinoma (zollinger-ellison syndrome). short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. treatment of scleroderma oesophagitis. new indications as at 2 november 1993: 1. short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. treatment of gastrinoma (zollinger-ellison syndrome). 5. short- term symptomatic treatment of reflux oe

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ranitidine hydrochloride, quantity: 168 mg (equivalent: ranitidine, qty 150 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; hypromellose; castor oil; iron oxide yellow; titanium dioxide; purified talc - indicated for short-term treatment of proven duodenal ulcer and gastric ulcer; maintenance treatment to reduce the risk of relapse in duodenal ulcer; maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer; treatment of gastrinoma (zollinger-ellison syndrome); short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids; maintenance treatment to reduce the risk of relapse of reflux oesophagitis; treatment of scleroderma oesophagitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ranitidine hydrochloride, quantity: 336 mg (equivalent: ranitidine, qty 300 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; magnesium stearate; hypromellose; castor oil; iron oxide yellow; titanium dioxide; purified talc - indicated for short-term treatment of proven duodenal ulcer and gastric ulcer; maintenance treatment to reduce the risk of relapse in duodenal ulcer; maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer; treatment of gastrinoma (zollinger-ellison syndrome); short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids; maintenance treatment to reduce the risk of relapse of reflux oesophagitis; treatment of scleroderma oesophagitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 336 mg (equivalent: ranitidine, qty 300 mg) - tablet, effervescent - excipient ingredients: povidone; sodium bicarbonate; aspartame; sodium benzoate; monosodium dihydrogen citrate; flavour - 1. short-term treatment of provenduodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. maintenance treatment to reduce the risk of relapse in duodenal ucler. 3. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. treatment of gastrinoma (zollinger-ellison syndrome). 5. short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. treatment of scleroderma oesophagitis. the intravenous injection is indicated where oral treatment is inappropriate.